Zydus Lifesciences and Lupin sign a supply and license agreement for saroglitazar mg

 Zydus Lifesciences and Lupin sign a supply and license agreement for saroglitazar mg

Zydus's groundbreaking medication, saroglitazar mg, has received approval from the DCGI to treat chronic liver illnesses, including non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steato hepatitis (NASH).

The medication was introduced by Zydus under the brand names Lipaglyn and Bilypsa, and the firms announced in a joint statement that Zydus would keep marketing them.

Major pharmaceutical companies Lupin Ltd. and Zydus Lifesciences Ltd. announced on November 3 that they had signed a supply and license agreement to jointly commercialize Saroglitazar Mg in India for the treatment of symptoms of nonalcoholic steatohepatitis as well as nonalcoholic fatty liver disease.

As per the deal, Lupin will be able to co-market the product in India under the LINVAS brand, with semi-exclusive rights.

The two businesses released a joint statement stating that Zydus introduced the medication under the brand names Lipaglyn as well as Bilypsa and would continue to sell them. Zydus's groundbreaking medication, saroglitazar mg, has received approval from the DCGI to treat chronic liver illnesses, including non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steato hepatitis (NASH). It also said that India was the first nation to get a medication licensed for these unfulfilled medical demands.

"Lupin will pay Zydus ahead licensing fees and milestone payments on the basis of the achievement of predetermined phases milestones," said the statement.

"This collaboration underscores our commitment to developing and broadening our services to address unmet patient requirements in India. Through this collaboration, we can further expand our gastroenterology portfolio and provide our patients and medical professionals with more access to healthcare solutions," Lupin Managing Director Nilesh Gupta said.

The collaboration with Lupin, according to Sharvil Patel, Managing Director of Zydus, would make this innovative medication accessible and hence increase its market share.

"Our breakthrough findings are helping patients to lead healthier and more satisfying lives. The quality of life for individuals with NAFLD and NASH has significantly improved because to saroglitazar magnesium, one of the essential medications, Patel said.

According to the release, Saroglitazar Mg's once-daily, 4 mg dosage schedule improves patient convenience, lowers pill load, and promotes higher compliance.

In September 2013, Saroglitazar Mg was introduced in India to treat patients with type-2 diabetes who were not responding to statins alone for their hypertriglyceridemia and diabetic dyslipidemia. Since then, the medicine has helped approximately 15 lakh people, according to the businesses.